Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.


Confirmed Presenting Companies:

 Session Chair Profile

Ph.D., Founder and CEO, Insilico Medicine, Inc

Biography
Alex Zhavoronkov, PhD, is the founder&CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and insurance industry. Since 2015 he has invented critical technologies in the field of GANs and reinforcement learning for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. He has published over 130 peer-reviewed research papers and 2 books. He serves on the editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and co-chairs the Annual Aging Research,Drug Discovery, and AI Forum.


 Speaker Profile

Partner, McKinsey and Company

Biography
Ziv Yaar is an Expert Partner and has been involved in Digital and Advanced Analytics for over 20 years and in the pharma for over 15 years. Ziv brings experience and expertise as a proven client service leader, experienced at managing large, complex studies with dozen of resources, solving a wide array of pharma problems. He also has a strong cross-channel marketing strategy and analytics background, as well as extensive technology background, which enable him to understand and work with technology teams and help business and marketing stakeholders understand the how technology can affect their business.


AI and Data Sciences Showcase:
McKinsey and Company

McKinsey and Company is a global management consulting firm.

Data Transformation
There is a lot of interest these days at the senior-most leadership of many Pharmaceutical companies in using machine learning and other advanced analytics methods to achieve strategic differentiation. A recent McKinsey analysis found, however that in order for a company to achieve this level, they would need to conduct ~1,000 advanced analytics use-cases per year. This is not tenable today because most Pharmaceutical companies’ take between 4-6 months to perform a typical (non-clinical trial) analytics use-case, instead of the 4-6 week cycle time that they would need in order to achieve advanced analytics at scale.

 Speaker Profile

COO, MMRF

Biography
Michael Andreini joined the MMRF as the Chief Operating Officer in 2019, and is responsible for overseeing day-to-day operations, strategic programs, and alliances across the foundation. Michael brings over 12 years of strategic consulting and operational experience in the life sciences industry. Prior to joining the MMRF, Michael was an Associate Principal at IQVIA in the consulting services organization where he led complex engagements for biopharma, medical device, and non-profit organizations across diverse solution areas including commercial assessments, portfolio analysis, R&D and launch strategy, and operational execution. Before joining IQVIA, Michael worked at Fuld & Company, a boutique consulting firm specializing in competitive intelligence and strategy, and prior to that, at Siemens Healthcare Diagnostics in the Global technical Operations group where he resolved technical issues for immunoassay reagents and systems. Michael earned a B.A. in chemistry with a minor concentration in economics from Colgate University.


AI and Data Sciences Showcase:
MMRF

A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for every multiple myeloma patient by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer.

Innovation Of Patient-Centered Research Initiatives: MMRF CureCloud
The first-of-its-kind, innovative MMRF CureCloud research study features direct-to-patient enrollment, the first at-home CLIA-grade cfDNA sequencing test for myeloma, and real-world EHR data collection to deliver real-time insights back to patients and their physicians to inform clinical decision-making.

 Speaker Profile

Ph.D., COO/CSO, AMPEL BioSolutions

Biography
Dr. Grammer is an internationally recognized scientist and successful entrepreneur, having founded and managed AMPEL successfully for over 5 years. Dr. Grammer was elected to the class of 2021 for SIBF (Society of International Business Fellows), an organization of 1,400 individuals in 45 countries worldwide. She was also awarded a Virginia SBIG grant for AMPEL's first investment round. She is a second term board member of Virginia Bio.Before co-founding AMPEL in 2013, Dr. Grammer spent over 20+ years in genomics and managed more than 15 National Institute of Health (NIH) scientific teams and a highly productive NIH laboratory. Dr. Grammer received multiple awards for her team's work comparing genes expressed in patients compared with healthy individuals, including the prestigious NIH Director's Award as well as mentoring awards from the American Association of Immunologists. She has published over 75 articles on her scientific research.


AI and Data Sciences Showcase:
AMPEL BioSolutions

AMPEL is a precision medicine company with a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that determine disease status, identify molecular pathway and predict best drugs. Genomic platform, bioinformatics, RNA analytics and ML/AI algorithms covered by patents & are disease agnostic.

LuGENE Px for Lupus
AMPEL’s LuGENE® Px blood test evaluates Lupus disease status, identifies molecular pathways and predicts drug options. Filed patents protect AMPEL’s genomic platform, bioinformatics, RNA analytics and machine learning algorithms as well as disease specific applications in oncology, autoimmunity and infectious disease.

 Speaker Profile

Ph.D., Founder & CEO, QUIBIM

Biography
Angel Alberich-Bayarri is a bioengineer, researcher and entrepreneur in medical image processing and the application of AI methods to radiology. He has experience in the lab-to-market translation of AI models covering unmet clinical needs in neurology, respiratory diseases, musculoskeletal and oncology scenarios. He is author of more than 60 publications in the field of imaging biomarkers, author of more than 15 book chapters and editor of 2 books. He is board member of several scientific societies and panels, such as the European Society of Medical Imaging Informatics (EUSOMII) and the European Imaging Biomarkers Alliance (EIBALL). In March 2020, he was one of the main promoters of the Imaging COVID-19 AI initiative, which currently hosts the biggest worldwide database of COVID-19 CT examinations and is leading the development of a highly accurate model for disease severity scoring and in-patients follow-up. He was named one of MIT Technology Review’s 35 most innovative people in the world under age 35, in 2015.


AI & Data Science Showcase:
QUIBIM

QUIBIM provides an AI platform focused on converting medical images into meaningful data. The company has a portfolio of accurate quantitative imaging solutions across neurology, lung, musculoskeletal and oncology disease areas.

AI and Medical Imaging for Innovation in COVID-19
The presentation will review the main challenges in the field of AI in medical imaging in the most relevant disease scenarios as well as the need for accelerating the lab-to-market transition of tools that can support COVID-19 patients management during the pandemic situation.

 Speaker Profile

MBA, CEO, BeanStock Ventures

Biography
Shawnnah Monterrey is the CEO and founder of BeanStock Ventures, with 20+ years’ experience in medical and life science software product development. BeanStock Ventures is an FDA accredited third party 510(k) review organization. Prior to founding BeanStock Ventures, she obtained a bachelor’s degree in computer science from the University of California, San Diego and an Executive MBA from San Diego State University, then went on to hold product development management positions across numerous global firms, including Illumina, Invetech, Medtronic and Carl Zeiss Meditec. During her time at Carl Zeiss Meditec, Shawnnah and her team successfully launched and obtained several 510(k) clearances for an AI based glaucoma diagnostics and monitoring application, using a neural network and support vector machine, in the early 2000s.


AI & Data Science Showcase:
BeanStock Ventures

BeanStock Ventures is an FDA accredited 3rd party review and software product development organization in the life science, digital health and medical device industry.

FDA Regulation, A Peek into AI Proposed Regulatory Framework
Artificial intelligence applications rely on diverse datasets to make informed decisions. As datasets grow, algorithms improve in sensitivity and specificity. The challenge remains, how to handle this from a regulatory perspective without hindering innovation and delaying products into the market?

 Speaker Profile

Ph.D., Chief Data Scientist & Co-Founder, OneThree Biotech

Biography
Cory Gilvary’s research has primarily focused on developing new machine learning techniques for increasing the efficiency and innovation of drug development and discovery. She takes the unique approach of combining distinct types of noisy, high-throughput data to maximize algorithmic performance, while also building interpretable models that allow for a deeper mechanistic insight to the mode of action of therapeutics. She has leveraged cutting edge AI concepts across diverse disease areas including, but not limited to, oncology, diabetes and Parksinson’s disease. Outside of her biological research, she spent time developing cutting edge machine learning models at one of the world’s leading quantitative hedge funds. Currently, Cory leads OneThree’s data science and computational biology efforts and much of her early research work formed the core OneThree platform. At the beginning of 2020, she spearheaded OneThree’s internal efforts to provide free toxicity screening to any researchers working on treatment for COVID-19.


AI & Data Science Showcase:
OneThree Biotech

OneThree Biotech is a VC backed startup working to change how new medicines are discovered using biology-driven AI. We are clinically validated and work with biotech and pharmaceutical companies to apply our mechanism focused AI to both pre-clinical and clinical pain points.

Interpretable AI for Early Stage Oncology Target Discovery
OneThree has created a platform of mechanism focused algorithms to address key questions within drug discovery. Our interpretable AI, allows us to elucidate the underlying mechanism of our predicted novel targets, a target's expected toxicity, and the ideal patient populations for positioning.

 Speaker Profile

Ph.D., CEO & Founder, PrecisionLife

Biography
Steve has over 25 years’ experience building world-class teams, products and companies including as Global Director of Research Informatics for Astra. He has raised venture funding in the UK, EU and USA to develop and market highly innovative and commercially successful products in the life science, healthcare and food industries. He has developed world-leading genomics, digital health, smart IoT and informatics technologies including several patented inventions. He was heavily involved in developing some of the core informatics systems used by major genomics companies during the initial Human Genome project and has worked extensively with major pharma companies on over 25 drug discovery and safety projects. Steve specializes in AI enabled drug discovery and precision medicine, large-scale genomics, semantic data integration and complex data analytics for life science and healthcare. He is interested in all aspects of precision medicine for chronic disease including novel drug targets, biomarkers and genetic risk scores.


AI & Data Science Showcase:
PrecisionLife

PrecisionLife’s unique combinatorial analytics platform generates deep insights into the complex biology of chronic diseases, driving the next wave of precision medicine applications and finding new treatment opportunities for patients’ unmet medical needs.

Chronic Disease Precision Medicine Needs Combinatorial Analytics
PrecisionLife’s unique combinatorial analytics platform generates deeper insights into the complex biology of chronic diseases, driving the next wave of precision medicine. All significant variant combinations are mapped to patient sub-groups, capturing the non-linear effects of the underlying biology.

 Speaker Profile

Ph.D., CEO, Deepcell

Biography
Maddison is co-founder and CEO of Deepcell. She invented Deepcell’s AI-based single-cell analysis and sorting technology with her postdoctoral advisor Euan Ashley and Mahyar Salek, and spun the company out of Stanford University in 2017. She has a multidisciplinary background with experience in electrical engineering, computer science, and bioengineering. Maddison holds a bachelor’s degree in electrical engineering from Sharif University of Technology, as well as a master’s degree in computer science and a PhD in bioengineering from the University of California, Los Angeles. She has published several papers in top-tier journals and has co-invented multiple patented technologies.


AI & Data Science Showcase:
Deepcell

Deepcell offers an AI-powered imaging and microfluidics platform that identifies and isolates viable cells based on morphological distinctions for use in translational research, diagnostic testing, and therapeutics.

Deep Learning Enables Label-free, Real-time Cell Characterization and Isolation
We present a novel technology for real-time identification and sorting of unlabeled single cells in flow using high-resolution imaging and a Convolutional Neural Network (CNN) across multiple cell types including immune cells, malignant cells, among others.

 Speaker Profile

CEO, Omics Data Automation

Biography
Before starting Omics Data Automation, Gans was the chief architect of several generations of multi-core Xeon processors (2001 – 2013) starting with the first multicore server which resulted in more than 92% server market share for Intel. Starting 2014, he focused on Genomics and Precision Medicine driven by “Big Data”. As Director of the Precision Medicine group at Intel, he led the “Collaborative Cancer Cloud” a federated cloud platform for cancer research, collaborating with OHSU (Oregon Health Science University, OR), Broad Institute, [email protected] and various Cancer medical centers including Dana Farber Cancer Institute in Boston and OICR (Ontario Institute for Cancer Research) in Toronto. He also led Heterogeneous computing group and three Intel collaborations with academic centers at UC Berkeley, Technion Israel and UCLA in this area.


AI and Data Science Showcase:
Omics Data Automation

ODA makes tools that aggregate data from EHR, omics and imaging to provide analytics that improve patient outcomes, reduce cost and expand access.

 Speaker Profile

M.D., Ph.D., SVP, Chief Medical Officer, SOPHiA GENETICS

Biography
Dr. Philippe Menu, MD, PhD, MBA, brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases. Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in life sciences from the Open University Business School.


AI & Data Science Showcase:
SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 750 hospital, laboratory and biopharma institutions globally.

Leveraging Multimodal Insights for Drug Development
Discover how we partner with the biopharma community to identify biomarkers and pioneer multimodal predictive analytics.

 Speaker Profile

VeriSIM Life

Biography
Speaker VeriSIM Life


AI & Data Science Showcase:
VeriSIM Life

VeriSIM Life is on a mission to advance human health by accelerating drug development with AI-enabled technology. VeriSIM Life AI-drived, biosimulations that derisk drug research and development decision by predicting the clinical outcomes of new drugs before human trials.

 Speaker Profile

Co-Founder and Chief Technology Officer, Syntegra

Biography
Ofer Mendelevitch has led technical development at Syntegra since its inception, where he has pioneered the use of generative language models to create synthetic healthcare data. Prior to joining Syntegra, Ofer served as Vice President of Data Science at Helix, a population genomics company. He has extensive experience leading complex state-of-the-art machine learning software projects across industries, having previously led data science and engineering teams at several companies, including LendUp, Hortonworks and Yahoo!. Ofer has published several papers and is the author of the book, “Practical Data Science with Hadoop and Spark.”


AI & Data Science Showcase:
Syntegra

Syntegra is the first healthcare company to leverage the breakthrough of machine learning language models (similar to GPT-3) to create patient-level, synthetic healthcare data that maintains full statistical fidelity and patient privacy, enabling increased data use and value across healthcare.

Innovative Machine Learning Models to Democratize Healthcare Data
AI-enabled synthetic data offers a unique solution to the long-standing challenges inhibiting access to healthcare data. We will discuss how modern language models are used by the Syntegra engine to generate synthetic healthcare data with high fidelity and guaranteed privacy.

 Speaker Profile

Chief Science Officer, BC Platforms

Biography
Timo Kanninen is CTO and co-founder of BC Platforms. He is the visionary behind BC Platforms’ data management systems. He has long-term experience in software development, genetic epidemiology, statistical genetics, and clinical statistics. Mr. Kanninen has also worked with hospital and occupational health IT systems. Mr. Kanninen is the founder and CEO/CTO of Statwell Oy (1990‐2002). The company provided statistical consultation and developed software for data collection and statistical analyses of personnel and occupational health questionnaires. The company was merged into BC Platforms in 2002. Mr. Kanninen studied information technology in production and statistics. He is a co-author on 16 scientific articles published in high-level journals.


AI & Data Science Showcase:
BC Platforms

BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine and drug development, accelerating the translation of insights into clinical practice.

 Speaker Profile

Ph.D., President and CEO, VIDA

Biography
Experienced Chief Executive with a demonstrated history of working in the AI and computer aided diagnosis and therapeutic evaluation using imaging. Strong business development professional skilled in imaging, pulmonary applications, HCIT, Oncology, Biotechnology, and Picture Archiving and Communication System (PACS).


AI & Data Science Showcase:
VIDA

VIDA treats the whole person — and a whole population — by bringing together mental and physical healthcare through the best of technology and the human touch of therapists and coaches.

 Speaker Profile

Ph.D., Senior Scientist, Helomics and Senior Scientist, TumorGenesis, Predictive Oncology

Biography
TBA


 Speaker Profile

M.D., Chief Medical Science Officer, Sema4; Clinical Professor of Medicine, Tisch Cancer Inst., Mount Sinai

Biography
William K. Oh, M.D. is Chief Medical Science Officer at Sema4, a patient-centered health intelligence company focused on precision medicine. He is also an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. He continues to see cancer patients in his capacity as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai. William has authored more than 330 articles, reviews, books and book chapters related to genitourinary cancers. He has conducted multiple clinical cancer trials and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association.


 Speaker Profile

M.B.A., Co-Founder, CEO; Endpoint Health

Biography
Jason is an accomplished start-up founder and executive with experience developing and commercializing disruptive products to solve healthcare’s most challenging problems. He is currently co-founder, board member and CEO of Endpoint Health, a Precision First therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each individual patient’s biology. Prior to Endpoint Health, co-founded GeneWEAVE, a diagnostics company that developed novel solutions to improve diagnosis and therapy choice in drug-resistant infections. Started in 2010, GeneWEAVE raised $25M in venture financing and was acquired by Roche in 2015. Jason received an MBA from Cornell University and currently lives in San Jose, CA with his wife and daughters.


AI & Data Science Showcase:
Endpoint Health

Endpoint Health is a precision first therapeutics company dedicated to addressing urgent needs in immune-driven illnesses by delivering therapies that are personalized to each patient’s biology by combining therapeutics and AI into an integrated platform.

Rewriting the Rules in Precision-First BioPharma
Learn how Endpoint Health is building a clinical and data ecosystem to dramatically accelerate development of life-changing immunology therapies personalized to each patient’s biology. Combining therapeutics and AI, the Company is unlocking value for patients, doctors, and healthcare systems.

 Speaker Profile

CEO, IMIDomics

Biography
Juan Harrison is a biotechnology and pharmaceutical executive focused on company formation, strategy, partnering, venture investment and licensing transactions. In his current role at IMIDomics, he is leading the company as it works to discover and develop new medicines for the treatment of patients with immune-mediated inflammatory diseases. He was previously Vice President and head of Strategic Academic Alliances (SAA) at Takeda Pharmaceuticals where he was responsible for establishing several broad drug discovery alliances. Before leading Takeda’s SAA, he was vice president at Takeda Ventures where he invested in several companies including Envoy Therapeutics, later acquired by Takeda. Harrison has also held senior positions in Alza Pharmaceuticals, Connetics, PowderJect and XenoPort.


AI & Data Science Showcase:
With strong roots in Spain and an established presence in the United States, IMIDomics is a global biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs).

With strong roots in Spain and an established presence in the United States, IMIDomics is a global biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs).

IMIDomics’ Precision Discovery Platform Enables Precision Medicine
IMIDomics believes that a deep understanding of patients, their clinical condition and underlying biology will lead to next generation medicines. Juan Harrison will showcase how IMIDomics discovers and develops precision medicines for IMIDs using its proprietary data-powered system.

 Speaker Profile

Ph.D., CEO and Co-Founder, Healx

Biography
Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using AI to accelerate treatments for rare diseases. He is Co-Founder and Chief Executive of Healx, the mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. In this role, Tim has been listed in The Sunday Times Maserati 100 list in 2019, was featured in The Telegraph’s Tech 100 in 2019, and was named as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020. Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease.


AI and Data Sciences Showcase:
Healx

Healx combines frontier AI technology with deep drug discovery and development expertise to accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development.

Pioneering the Next Generation of Drug Discovery for Rare Disease
There are 7,000 rare diseases, affecting over 400 million people worldwide - and 95% of those diseases don’t have an approved treatment. Hear how Healx are developing a new approach to drug discovery in order to address this huge unmet need.

 Speaker Profile

Ph.D., Data Scientist, Ardigen

Biography
Dr. Krzysztof Rataj works at the intersection of medicinal chemistry, biology, imaging and artificial intelligence in the field of drug discovery. He obtained a PhD in Biophysics from Jagiellonian University, and worked on numerous projects in collaboration with scientific teams from Hungary, Denmark and Norway. His team explores the application of artificial intelligence approaches to various aspects of drug design and precision medicine, such as transformers for property prediction and compound optimization, natural language processing methods in protein and nucleic acid research, and computer vision in high content screening and histopathology. Their current endeavor is the marriage of chemical structure and phenotypic screening images in order to create a comprehensive approach to high content screening.


AI & Data Science Showcase:
Ardigen

Ardigen is harnessing advanced AI methods for novel precision medicine. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective therapies.

Enhancing Phenotypic Drug Discovery with AI-based Methods
The resurgence of phenotypic screening as a viable method of early drug discovery opens up a new field for application of AI-based methods. We would like to explore the concept of merging high content image data with chemical compound data to provide new quality in HCS pipelines.

 Speaker Profile

Ph.D., Director of Scientific Strategy and Business Development, Aiforia

Biography
Dr. Thomas Westerling-Bui received his PhD in cancer biology, focusing on the cell cycle and transcription, from the University of Helsinki Medical School in Finland. He completed a post-doctoral EMBO fellowship at the Dana Farber Cancer Institute in Boston, researching the genomics of breast and prostate cancer. Thomas joined Aiforia to advance the new potential of cancer biology, pathology, big data, and artificial intelligence.


AI and Data Sciences Showcase:
Aiforia

Aiforia equips pathologists and scientists with powerful deep learning artificial intelligence for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia software aims to escalate the efficiency and precision of preclinical and clinical medical image analysis from oncology to neuroscience and more.

Bringing Precision to Diagnostics with Deep Learning
Deep learning artificial intelligence enables increased speed, accuracy and consistency in medical image analysis. Aiforia's automated, AI-driven solutions supports pathologists in diagnosing some of the most prevalent cancers like breast and lung with greater efficiency and precision; paving the path for personalized therapy.

 Speaker Profile

Vice President, Strategic Marketing and Alliances at OnRamp, ROSALIND

Biography
Jay is Vice President of Strategic Marketing and Alliances at OnRamp. He is passionate about leveraging new technologies to accelerate discovery of new diagnostics and treatments. Previously, he served as Senior Director of Product Management and Business Unit Leader for NanoString’s nCounter business. At NanoString, he led development and commercialization of many new products and also designed and implemented new processes to help the company scale from a small start-up to a public company. Prior to NanoString, Jay worked at PATH in a role focused on establishing public-private partnerships for development of diagnostic tests for infectious diseases in low resource settings around the world. Early in his career he performed genomic and proteomic research at University of Washington, Seattle Biomed, and Ambit Biosciences.


AI and Data Sciences Showcase:
ROSALIND

 Speaker Profile

Sr. Manager & Head, Academic Medicine, Amazon Web Services (AWS)

Biography
Speaker Amazon


AI and Data Science Showcase:
Amazon

 Speaker Profile

Senior Vice President & General Manager, Data Products & AI, Tempus

Biography
Abdul Hamid Halabi serves as the Senior Vice President & General Manager, Data Products and AI. Prior to Tempus, Abdul was the Global Head of Healthcare, AI and Robotics at NVIDIA. Abdul launched NVIDIA’s Health platform, Clara, to reach thousands of developers and deployment sites. He also grew NVIDIA’s healthcare industry presence to a healthy 9-figure and accelerating business. Abdul holds a B.S. in Computer Engineering from the University of Toronto, a Master’s in Management Science and Engineering from Stanford University and an MBA from Texas A&M-Commerce.


 Speaker Profile

Quinten Healthcare

Biography
Speaker Quinten Healthcare


 Speaker Profile

Senior Manager, Biopharma Partnerships, PathAI

Biography
Rob Brockett, M.S., is a Senior Manager of Biopharma Partnerships at PathAI, a company transforming drug development and diagnostics through AI-powered pathology. He has spent the last 10 years focused on integrating digital pathology and machine learning solutions to support drug development programs, both as a scientist for Gilead Sciences and MilliporeSigma and through technical sales with Visiopharm. Rob earned his Bachelor of Science degree in biology from California State University San Marcos and his Master of Science degree in clinical and translational research from George Washington University.


AI and Data Science Showcase:
PathAI

PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning.